The Impact of COVID-19
on Clinical Research

 

CLICK TO LEARN MORE

What is the

Heart Failure Collaboratory (HFC)?

Efficiency of clinical trials and evidence generation in heart failure and foster development of therapies by creating a collaborative environment in which FDA, government agencies including NIH and CMS, and the heart failure community can interact to optimize innovation and advancement of new therapeutic products. HFC has established five working groups to tackle individual issues in clinical trials and fostering the development of effective heart failure therapies.


The Heart Failure Collaboratory is a public-private partnership with the FDA and the consortium to help foster the development of new products for heart failure.

Recent Publications

Access our latest publications, downloads and meeting notes.
Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel
The coronavirus disease-2019 (COVID-19) pandemic has profoundly changed clinical care and research, including the conduct of clinical trials, and the clinical research ecosystem will need to adapt to this transformed environment.
Heart Failure Collaboratory Statement on Remote Monitoring and Social Distancing in the Landscape of COVID-19
Patients with heart failure (HF) are extraordinarily vulnerable to the effects of COVID-19.
Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation
The study sought to demonstrate the statistical and utilitarian properties of restricted mean survival time (RMST) and restricted mean time lost (RMTL) for assessing treatments for heart failure (HF) with reduced ejection fraction.